Xiaomeng Liao

BresMed — United Kingdom

Medicine · Health Sciences

1h-index2citations4works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(2), Myeloproliferative Neoplasms: Diagnosis and Treatment(2), Schizophrenia research and treatment(1), Gastrointestinal motility and disorders(1), Bipolar Disorder and Treatment(1)

Publications4 total

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
HemaSphere·2022Open Access
P.0710 Exploring the rapidity of treatment effect for current treatment options for major depressive disorder
European Neuropsychopharmacology·2021
Indirect Treatment Comparisons of the Effect of Fedratinib Versus Navitoclax Plus Ruxolitinib on Spleen Volume and Symptoms in Patients with Myelofibrosis and Prior Ruxolitinib Treatment
Blood·2021
Protocol for individual participant data meta-analysis of randomised controlled trials of patients with psychosis to investigate treatment effect modifiers for CBT versus treatment as usual or other psychosocial interventions
BMJ Open·2021· 2 citedOpen Access

Frequent Co-authors

Stephen J. Smith(2), Maria Sudell(1), Catrin Tudur Smith(1), Eleanor Longden(1), Graham Dunn(1), Tim Kendall(1), Richard Emsley(1), Anthony P. Morrison(1), Filippo Varese(1), Pranav Abraham(1), Manoj Chevli(1), Sarah Smith(1), Miranda Cooper(1), Alix Arnaud(1), Ellison Suthoff(1), H. Kilvert(1), P. Abraham(1), Maulik Chevli(1)